X
X

Tom O'Brien

CEO

Prior to founding Eclipse in 1993, Tom held several leadership positions throughout his career in the medical device industry. Having mastered both disposable and capital equipment sales for companies like C.R. Bard, Tom’s track record of success quickly established Eclipse as the go-to company to launch new technology in the surgical laser industry.

Over time Tom transitioned Eclipse from a leader in the OR surgical laser market to a key player in the aesthetic laser industry. Starting in 2011 Eclipse began a new mission of increasing adoption of Platelet-rich Plasma on a national level.

His vision and leadership has helped Eclipse become one of the most successful medical device companies in its space. Tom’s new mission is to bring game-changing Eclipse technologies in Platelet-Rich Plasma, Microneedling and Shockwave Therapy to the entire globe.

X

MICROPEN® ELITE SAFETY

Intended Use

Eclipse MicroPen® Elite is an Epidermal Micro-Exfoliation (EME) device used to stimulate the tissue and improve the appearance of scars.

Contraindications

Treatment with this device should not be used for patients with any of the following conditions:

  • Keloid scars
  • History of eczema, psoriasis and other chronic conditions
  • History of actinic (solar) keratosis, diabetes, raised moles or warts on targeted area
  • History of hemophilia, irregular blood pressure, tuberculosis, liver function issues
  • Susceptibility to capillary ectasia due to steroid use for extended periods
  • Scleroderma
  • Collagen vascular disease
  • Cardiac abnormalities, pacemaker, blood clotting problems
  • Blood thinning medication
  • Active bacterial or fungal infection
  • Immunosuppression
  • Facial melanosis
  • Malignant tumors
  • History of any type of cancer or suspicious lesions or moles in treatment area
  • Pregnant or nursing women
  • Any other medical condition contraindicated by the treating physician

Precautions & Warnings

  1. Discontinue auto-immune therapies or retinoid (Retin-A) and/or any form of skin treatment 24 hours prior to procedure, under care and direction of a physician.
  2. Do not treat active acne, rosacea, or other inflammatory skin conditions. Do not treat subject with piercings in treatment area or open wounds.
  3. Not to be administered for 6 months after isotretinoin (Accutane) regime.
  4. Patients with facial outbreaks such as herpes simplex virus, medication must be taken per doctor’s instructions.
  5. Patients with metal allergies or skin allergies.
  6. Subjects on any medications that would affect the characteristics of the skin should be stopped for two months prior to treatment under the care and direction of a physician.
  7. Subjects who had a face lift or eyelid surgery within the past year, or dermabrasion, remodeling, deep chemical peels, or any surgical procedure on the treatment area within the previous 3 months.
  8. Subjects who had Botox, collagen, fat, or other methods of augmentation with injected materials in the treatment area in previous 6 months.
  9. Subjects who have excessively tanned or sunburned skin from the sun, tanning beds, or tanning creams within previous 2 weeks.
  10. Patients are to avoid sweaty exercise and sun exposure for 72 hours post-procedure.
  11. Fitzpatrick skin types V-VI, pigment may darken prior to lightening.
  12. Patients could experience redness between one to three days.
  13. Patients may experience inflammation, itching, and burning.

Want to become a provider?

Learn More